Research programme: urotensin II receptor agonists - Acadia Pharmaceuticals
Alternative Names: AC-7954Latest Information Update: 04 Apr 2012
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action GPR14 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders; Diabetes mellitus; Diabetic nephropathies
Most Recent Events
- 24 May 2010 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 24 May 2010 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 24 May 2010 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)